Expertise in
13
conditions

Dr. Erica D. Warlick

Hematology
U Of M Health Clinics And Surgery Center Inc.
909 Fulton St SE, 
Minneapolis, MN 
21 Years of Experience
Expertise in
13
conditions
U Of M Health Clinics And Surgery Center Inc.
909 Fulton St SE, 
Minneapolis, MN 

Overview

Erica Warlick is a Hematologist practicing medicine in Minneapolis, Minnesota. She has been practicing medicine for over 21 years.

Dr. Warlick is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Bone Marrow Aspiration, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 88 peer reviewed articles and participating in 4 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in MN

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

U of M Health Clinics and Surgery Center Inc.
909 Fulton St SE, Minneapolis, MN 55455
Other Locations
University of Minnesota Masonic Children's Hospital
420 Delaware St SE, Minneapolis, MN 55455

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]
Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug, Biological, Radiation
Study Drugs: Allopurinol, Fludarabine, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Anti-Thymocyte Globulin
Study Phase: Phase 2
GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis
GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis
Enrollment Status: Terminated
Publish Date: November 10, 2022
Intervention Type: Drug
Study Drug: GTB-3550 TriKE CD33-Positive Myeloid-Derived Suppressor Cells
Study Phase: Phase 1/Phase 2
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: February 12, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

88 Total Publications

A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia.
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia.
Journal: Blood advances
Published: November 25, 2024
Similar Doctors
Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Fairview Pharmacy Services LLC

516 Delaware St SE, 
Minneapolis, MN 
 (0.3 miles away)
612-626-2663
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Weisdorf is a Hematologist practicing medicine in Minneapolis, Minnesota. Dr. Weisdorf is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Transplant, and Bone Graft. Dr. Weisdorf is currently accepting new patients.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

M Health Fairview Center For Bleeding And Clotting Disorders

2512 South 7th Street, Suite 105, 
Minneapolis, MN 
 (0.6 miles away)
612-273-5005
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Reding is a Hematologist practicing medicine in Minneapolis, Minnesota. Dr. Reding is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Hemophilia A, Blood Clots, Hemophilia B, Splenectomy, and Bone Marrow Transplant. Dr. Reding is currently accepting new patients.

Expertise in
9
conditions
Dr. Mukta Arora
Hematology | Oncology
Expertise in
9
conditions
Dr. Mukta Arora
Hematology | Oncology
Referral may be required

Fairview Pharmacy Services LLC

516 Delaware St SE, 
Minneapolis, MN 
 (0.3 miles away)
612-273-2800
Languages Spoken:
English
See accepted insurances

Mukta Arora is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Arora is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Erica D. Warlick

How do I make an appointment with Dr. Erica D. Warlick?

You can book an appointment with Dr. Erica D. Warlick by calling their office at 612-676-4200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Erica D. Warlick a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Erica D. Warlick is classified as an Elite expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Erica D. Warlick specialize in?

While Dr. Erica D. Warlick is a Hematology, they have specific expertise in Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and Chronic Myelogenous Leukemia (CML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Erica D. Warlick participate in research or clinical trials?

Yes. Dr. Erica D. Warlick has published 88 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Dr. Erica D. Warlick's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Erica D. Warlick accept my insurance?

Dr. Erica D. Warlick accepts most major insurance plans, including Blue Cross Blue Shield and UnitedHealthcare. We recommend calling the office directly at 612-676-4200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Warlick's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile